BUSINESS
Kyowa Kirin Says It’s Steadily Pursuing Nesp Authorized Biosimilar Program, but Silent on Details
Kyowa Hakko Kirin is steadily pursuing its Nesp (darbepoetin alfa) authorized biosimilar (AB) program towards its approval, company executives said at earnings conference on July 31, but they disclosed none of its details, including its development and filing status. “At…
To read the full story
Related Article
- Kyowa Kirin Sets Up New Firm for Nesp Authorized Biosimilar
February 1, 2017
BUSINESS
- Shionogi to Lift Stake in ViiV to 21.7% as Pfizer Exits
January 21, 2026
- Fuji Pharma Earns Approval for High-Dose Stelara Biosimilar
January 21, 2026
- Kaken’s Hyperhidrosis Drug Ecclock Now Available in South Korea
January 20, 2026
- Daridorexant Hits Primary Goal in South Korea PIII Insomnia Trial, Nxera Plans Filing in Q1 2026
January 20, 2026
- Enhertu Combo Accepted for EU Review in First-Line HER2 Breast Cancer
January 20, 2026
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…





